AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25457458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained hypotension
Number of subjects: 116
Study 25457633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib 500 mg once daily on a 5-days-on/2-days-off schedule
Number of subjects: 44
Study 25457633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib
Number of subjects: 44
Study 25458435 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurant stent graft
Number of subjects: 1263
Study 25458728 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal transplantation of hESC-derived retinal pigment epithelium (50,000, 100,000, and 150,000 cells)
Number of subjects: 18
Study 25458728 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal transplantation of hESC-derived retinal pigment epithelium
Number of subjects: 18
Study 25458728 — intervention group
Group type: COMPARATOR
Intervention: Untreated fellow eyes
Number of subjects: 18
Study 25458735 — intervention group
Group type: EXPERIMENTAL
Intervention: FXIII concentrate (human) 40 IU kg(-1) on Days 0, 28, and 56
Number of subjects: 14
Study 25459038 — intervention group
Group type: EXPERIMENTAL
Intervention: Melody transcatheter pulmonary valve (TPV) implantation
Number of subjects: 100
Study 25459109 — intervention group
Group type: EXPERIMENTAL
Intervention: (111)In-BzDTPA-pertuzumab (2.5MBq; 2μg)
Number of subjects: 0
Study 25459109 — intervention group
Group type: EXPERIMENTAL
Intervention: (111)In-BzDTPA-pertuzumab (1.0MBq, 20μg)
Number of subjects: 0
Study 25459109 — intervention group
Group type: COMPARATOR
Intervention: Control mice injected with unlabeled BzDTPA-pertuzumab (20μg) or Sodium Chloride Injection USP
Number of subjects: 0
Study 25459243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment assessment using the MUSIC score (mean score 20.6 ± 5.4)
Number of subjects: 78
Study 25459243 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion volumes (LV) and disability severity
Number of subjects: 78
Study 25459243 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference test from MUSIC subtests
Number of subjects: 78
Study 25460357 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated cord blood transplantation (UCBT) using reduced-intensity conditioning (RIC) consisting of total body irradiation (2 Gy), cyclophosphamide (50 mg/kg), and fludarabine (200 mg/m(2)).
Number of subjects: 79
Study 25460357 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated cord blood transplantation (UCBT) using reduced-intensity conditioning (RIC).
Number of subjects: 79
Study 25461210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (100-800 mg/day)
Number of subjects: 370
Study 25461221 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher perceived epilepsy-related stigma
Number of subjects: 140
Study 25461221 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma on adherence
Number of subjects: 140
Study 25461821 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophage migration inhibitory factor (MIF)
Number of subjects: 36
Study 25461821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines and chemokines
Number of subjects: 36
Study 25462205 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 25mg/m(2) followed by gemcitabine 1000mg/m(2) administered intravenously on days 1 and 8 every 3 weeks
Number of subjects: 44
Study 25462205 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine and gemcitabine combination chemotherapy
Number of subjects: 44
Study 25464386 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 mutations
Number of subjects: 112
Study 25464386 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKN2A deletions
Number of subjects: 112
Study 25464386 — intervention group
Group type: COMPARATOR
Intervention: Normal TP53/CDKN2A gene status
Number of subjects: 112
Study 25464481 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires on perceived health status (12-item Short-form Health Survey & EuroQOL-5D)
Number of subjects: 3500
Study 25464481 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires on psychological functioning (Hospital Anxiety and Depression Scale)
Number of subjects: 3500
Study 25464481 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires on health behaviors (Health-Behavior Scale-Congenital Heart Disease)
Number of subjects: 3500
Study 25464481 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires on quality of life (Linear Analog Scale & Satisfaction With Life Scale)
Number of subjects: 3500
Study 25464836 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation therapy (BA-W) for 12 weeks
Number of subjects: 16
Study 25465231 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose treatment arm
Number of subjects: 0
Study 25465231 — intervention group
Group type: EXPERIMENTAL
Intervention: Major molecular remission
Number of subjects: 0
Study 25465231 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25465273 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated patients with T1DM
Number of subjects: 3048
Study 25465273 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated patients with T2DM
Number of subjects: 3048
Study 25465273 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective survey for T1DM
Number of subjects: 3048
Study 25465273 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective survey for T2DM
Number of subjects: 3048
Study 25465273 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoglycaemia events in T1DM
Number of subjects: 3048
Study 25465273 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoglycaemia events in T2DM
Number of subjects: 3048
Study 25465273 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-reported severe hypoglycaemia in T1DM
Number of subjects: 3048
Study 25465273 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-reported severe hypoglycaemia in T2DM
Number of subjects: 3048
Study 25465496 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular pacing from the apex
Number of subjects: 408
Study 25465496 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular pacing from the septal site
Number of subjects: 408
Study 25466258 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)FDG-PET in patients with PNES
Number of subjects: 16
Study 25466258 — intervention group
Group type: COMPARATOR
Intervention: (18)FDG-PET in healthy controls
Number of subjects: 16
Study 25466314 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews conducted at 3, 6, 12, and 24 months after ICU discharge
Number of subjects: 12
Study 25466314 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 12
Study 25466314 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions designed to improve family outcomes after critical illness
Number of subjects: 12
Study 25466314 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention and support
Number of subjects: 12
Study 25466314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing family-centered follow-up programs
Number of subjects: 12
Study 25466382 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg once daily
Number of subjects: 37
Study 25466513 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dementia prevalence
Number of subjects: 0
Study 25466513 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD) prevalence
Number of subjects: 0
Study 25466513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular dementia (VD) prevalence
Number of subjects: 0
Study 25466513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment prevalence (CIND)
Number of subjects: 0
Study 25466513 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) prevalence
Number of subjects: 0
Study 25466513 — intervention group
Group type: EXPERIMENTAL
Intervention: CIND-other prevalence
Number of subjects: 0
Study 25466521 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 1921260
Study 25466757 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA detection
Number of subjects: 571
Study 25466757 — intervention group
Group type: EXPERIMENTAL
Intervention: Single HPV type infection
Number of subjects: 571
Study 25466757 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple HPV type infection
Number of subjects: 571
Study 25466757 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidentifiable HPV type infection
Number of subjects: 571
Study 25466757 — intervention group
Group type: EXPERIMENTAL
Intervention: Most prevalent HPV types
Number of subjects: 571
Study 25466757 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infection with other HR-HPV types
Number of subjects: 571
Study 25466757 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV awareness
Number of subjects: 571
Study 25466778 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A vaccination
Number of subjects: 0
Study 25468293 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside simulation-based training for CVL dressing change and maintenance bundle with intermittent training refreshers
Number of subjects: 0
Study 25468293 — intervention group
Group type: COMPARATOR
Intervention: Standard CVL bundle training process
Number of subjects: 0
Study 25468505 — intervention group
Group type: EXPERIMENTAL
Intervention: ALTAIR software platform for automatic image analysis of retinal vessel calibre
Number of subjects: 386
Study 25468505 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPCON TRCNW200 non-mydriatic retinal camera
Number of subjects: 386
Study 25468505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver and interobserver reliability assessments
Number of subjects: 386
Study 25468505 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent validity assessments
Number of subjects: 386
Study 25468505 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of carotid intima-media thickness, pulse wave velocity, cardio-ankle vascular index, digital ECG, microalbuminuria, and glomerular filtration
Number of subjects: 386
Study 25468512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 300 mg/day
Number of subjects: 27
Study 25468655 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of preamyloid oligomers (PAOs) in atrial tissue
Number of subjects: 92
Study 25468655 — intervention group
Group type: EXPERIMENTAL
Intervention: PAO burden quantified by mean green/red ratio
Number of subjects: 92
Study 25469734 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb Bioresorbable Vascular Scaffold System (Absorb BVS)
Number of subjects: 1000
Study 25469987 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index
Number of subjects: 181764
Study 25469987 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior costs
Number of subjects: 181764
Study 25469987 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic Cost Group (DCG)
Number of subjects: 181764
Study 25469987 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index, prior costs, and DCG
Number of subjects: 181764
Study 25470338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily for 6 weeks
Number of subjects: 36
Study 25470338 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 36
Study 25470818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zanamivir (IVZ) 600 mg twice daily for five days
Number of subjects: 21
Study 25471062 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Detection (ED) implemented by the First-episode Services (FES) STEP in southern Connecticut
Number of subjects: 0
Study 25471062 — intervention group
Group type: COMPARATOR
Intervention: Usual detection efforts at the comparable FES PREP(R) serving the greater Boston metropolitan area
Number of subjects: 0
Study 25472823 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels before examination
Number of subjects: 25
Study 25472823 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cortisol levels before examination
Number of subjects: 25
Study 25472823 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cortisol levels before examination
Number of subjects: 25
Study 25472823 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels after examination
Number of subjects: 25
Study 25472823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol levels and academic performance
Number of subjects: 25
Study 25472874 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF:Ag levels in ACS patients
Number of subjects: 581
Study 25472874 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF:Ag levels in SAP patients
Number of subjects: 581
Study 25473029 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin 200 mg every 48 h
Number of subjects: 20
Study 25473029 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin 300 mg every 72 h
Number of subjects: 20
Study 25473029 — intervention group
Group type: COMPARATOR
Intervention: Licensed regimen
Number of subjects: 20
Study 25473804 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 101
Study 25473804 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 101
Study 25473804 — intervention group
Group type: EXPERIMENTAL
Intervention: NGAL
Number of subjects: 101
Study 25473804 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NT-proBNP and NGAL
Number of subjects: 101
Study 25473804 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BNP and NGAL
Number of subjects: 101
Study 25473804 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 101
Study 25473804 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital length of stay (LOS)
Number of subjects: 101
Study 25474185 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled VOCs
Number of subjects: 202
Study 25474185 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression of toll-like receptor 4, catalase, and tumor necrosis factor-α
Number of subjects: 202
Study 25474185 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model with VOCs, gene expression, and API
Number of subjects: 202
Study 25474185 — intervention group
Group type: COMPARATOR
Intervention: Biomarkers in exhaled breath condensate and airway resistance (pre- and post-bronchodilator)
Number of subjects: 202
Study 25474373 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT (COPD Assessment Test)
Number of subjects: 1465
Study 25474373 — intervention group
Group type: EXPERIMENTAL
Intervention: mMRC (Modified Medical Research Council)
Number of subjects: 1465
Study 25474373 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment according to LLN (Lower Limit of Normal)
Number of subjects: 1465
Study 25475068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccines prepared by the adherence method
Number of subjects: 0
Study 25475068 — intervention group
Group type: COMPARATOR
Intervention: Dendritic cell vaccines prepared by the antibody-selected CD14+ method
Number of subjects: 0
Study 25475080 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV-positive DLBCL in young adults
Number of subjects: 571
Study 25475080 — intervention group
Group type: COMPARATOR
Intervention: EBV-positive DLBCL in elderly group
Number of subjects: 571
Study 25475080 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV-positive DLBCL in young group
Number of subjects: 571
Study 25475207 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine group (n=25)
Number of subjects: 50
Study 25475207 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=25)
Number of subjects: 50
Study 25475246 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department care
Number of subjects: 5632
Study 25475413 — intervention group
Group type: EXPERIMENTAL
Intervention: THC/CBD oromucosal spray
Number of subjects: 0
Study 25475413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25475601 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily for 5 days followed by warfarin loading dose of 5 or 10 mg once daily for 2-4 days (co-administration)
Number of subjects: 0
Study 25475601 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone (monotherapy)
Number of subjects: 0
Study 25475601 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 0
Study 25476715 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bilirubin levels >1.1 mg/dL in patients with no appendiceal inflammation (14%) vs any appendicitis (36%)
Number of subjects: 493
Study 25476715 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bilirubin levels >1.1 mg/dL in patients with non-perforated appendicitis (48%) vs perforated appendicitis
Number of subjects: 493
Study 25476715 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive likelihood ratio for elevated bilirubin in discriminating no appendiceal inflammation vs any appendicitis
Number of subjects: 493
Study 25476715 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive likelihood ratio for elevated bilirubin in discriminating non-perforated appendicitis vs perforated appendicitis
Number of subjects: 493
Study 25477010 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin/S-1 combination chemotherapy
Number of subjects: 50
Study 25478013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle fracture patients
Number of subjects: 41
Study 25478013 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimalleolar fracture group
Number of subjects: 41
Study 25478013 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimalleolar fracture group
Number of subjects: 41
Study 25478013 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 25478017 — intervention group
Group type: EXPERIMENTAL
Intervention: AADvac1 tau peptide vaccine
Number of subjects: 0
Study 25478028 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic educational programme
Number of subjects: 170
Study 25478028 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 170
Study 25478141 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks SMT + SRE
Number of subjects: 200
Study 25478141 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 weeks SMT + SRE
Number of subjects: 200
Study 25478142 — intervention group
Group type: EXPERIMENTAL
Intervention: Active chiropractic treatment
Number of subjects: 26
Study 25478142 — intervention group
Group type: COMPARATOR
Intervention: Sham chiropractic treatment
Number of subjects: 26
Study 25478169 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic interventions for IPF
Number of subjects: 500
Study 25478169 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry data collection
Number of subjects: 500
Study 25478169 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative analysis
Number of subjects: 500
Study 25478181 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for methylated p16 in sputum
Number of subjects: 35
Study 25478181 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational presentation regarding p16 function
Number of subjects: 35
Study 25478181 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk test results
Number of subjects: 35
Study 25478181 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk test results
Number of subjects: 35
Study 25478181 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation rates
Number of subjects: 35
Study 25478585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection
Number of subjects: 14
Study 25478681 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial tidal volume of 1 ml/kg PBW increase
Number of subjects: 482
Study 25478681 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent tidal volume of 1 ml/kg PBW increase
Number of subjects: 482
Study 25478681 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving 10 ml/kg PBW for 8 days
Number of subjects: 482
Study 25478681 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving 8 ml/kg PBW for 8 days
Number of subjects: 482
Study 25479117 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen
Number of subjects: 101
Study 25479117 — intervention group
Group type: COMPARATOR
Intervention: Nonrebreathing bag reservoir facemask
Number of subjects: 101
Study 25479121 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG hrPET
Number of subjects: 10
Study 25479121 — intervention group
Group type: COMPARATOR
Intervention: MRI (SE sequence)
Number of subjects: 10
Study 25479121 — intervention group
Group type: COMPARATOR
Intervention: MRI (SPGR sequence)
Number of subjects: 10
Study 25479633 — intervention group
Group type: EXPERIMENTAL
Intervention: interRAI Palliative Care instrument (interRAI PC)
Number of subjects: 15
Study 25480497 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted multi-agent immunochemotherapy regimen with temozolomide maintenance
Number of subjects: 66
Study 25480498 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum survivin levels
Number of subjects: 0
Study 25480498 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor levels
Number of subjects: 0
Study 25480772 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) monitoring
Number of subjects: 0
Study 25480772 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed NIRS information for monitoring cerebral autoregulation and tissue oxygenation
Number of subjects: 0
Study 25481376 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA) administered within 15 min of mifepristone administration
Number of subjects: 20
Study 25481712 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutations in pancreatic juice from patients with pancreatic cancer (n = 30)
Number of subjects: 272
Study 25481712 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutations in pancreatic juice from asymptomatic individuals at high risk for pancreatic cancer
Number of subjects: 272
Study 25481712 — intervention group
Group type: COMPARATOR
Intervention: KRAS mutations in pancreatic juice from controls (n = 48)
Number of subjects: 272
Study 25481712 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutations detected 3 or more times in patients with pancreatic cancer
Number of subjects: 272